MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.

The genomic biomarkers market is experiencing rapid growth, driven by advancements in precision medicine, early disease ...

CALIFORNIA, CA, UNITED STATES, May 29, 2025 /EINPresswire.com/ -- The global genetic testing market is anticipated to experience substantial growth by 2033, as the industry demand is driven by ...

Myriad Oncology provides a portfolio of advanced genetic and tumor genomic testing solutions, including risk assessment, ...

Myriad Genetics, Inc. (NASDAQ ... MIRISC tests were offset by softness in volume for GeneSight unaffected hereditary cancer tests. If we exclude the UnitedHealthcare impact of GeneSight, the ...

Shares of genetic testing company Myriad Genetics (NASDAQ ... EBITDA guidance due to weaker trends in its pharmacogenomics and hereditary cancer testing (women's health) businesses.

Myriad Genetics faced a challenging Q1 2025, impacted by GeneSight volume declines and slower-than-expected hereditary cancer testing. Revised guidance reflects these headwinds, but management ...

Myriad Genetics has a 12-month low of $7.35 and ... It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report ... It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline ...

Myriad Genetics earned $4 million from GeneSight ... delivered revenue of $82.8 million in the fourth quarter of 2024. Hereditary cancer testing revenue in Oncology grew 8% year-over-year.

Myriad Genetics. “Expanding access through CancerCARE’s network will give more patients the opportunity to take the MyRisk with RiskScore Hereditary Cancer Test.” MyRisk with RiskScore is ...